U.S. Dry Eye Disease Diagnostic Devices Market (Device Type: Anterior Segment OCT, Meibography Device, Corneal Topographer, Interferometer, Fluorophotometer, and Others; Disease and End-user)- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

According to Nova one advisor, the Dry Eye Disease Diagnostic Devices Market Size was valued at USD 60.3 billion in 2022 and is predicted to be worth USD 101.4 billion by 2032, with a CAGR of 6.4% from 2023 to 2032.  Rise in prevalence and incidence rates of dry eye disease in the U.S., technical advancements in dry eye disease diagnostic devices, adverse effects of rising pollution levels, and increase in use of electronics are anticipated to propel the market during the forecast period.

Rise in Prevalence and Incidence Rates of Dry Eye Disease in U.S: Key Drivers

• In the U.S., dry eye disease is considered a critical and significant public health issue. An article published in the American Journal of Ophthalmology stated that overall estimated prevalence of dry eye disease was 5.28% in the U.S. between 2003 and 2015.
• It also indicated that the prevalence and incidence vary from 5% to 50%, and the prevalence is rising due to higher incidence of some risk factors and gradual increase, especially in the geriatric population. Hence, rise in prevalence of dry eye disease is expected to drive the market.
• Surge in the geriatric population increases the risk of dry eye diseases. This, in turn, is likely to augment the dry eye disease diagnostic devices market in the U.S.
• According to the American Journal of Ophthalmology, in the U.S., prevalence of dry eye disease increased with age from 0.20% for ages two to 17 years to 11.66% for individuals aged over 50 years. The geriatric population represented 16% of the population of the U.S. The number of elderly people in the country has increased by 14.4 million, or 36%, since 2009 compared to a rise of 3% for the under-65 population.
• Therefore, surge in the geriatric population and rise in prevalence & incidence rates of dry eye disease in the U.S. are projected to drive the dry eye disease diagnostic devices market

Report Scope of the Dry Eye Disease Diagnostic Devices Market

Technical Advancements in Dry Eye Disease Diagnostic Devices: Major Driver

• Dry eye is one of the most common problems faced by ophthalmologists. Its multiple causes have made it a challenge to diagnose. Companies focus on addressing this challenge and find a diagnostic method, thereby creating a more precise device for it.
• Technological advancements enable ophthalmologists to provide fast, accurate, smooth diagnosis with enhanced efficiency. Hence, technological advancements is a significant driver of the dry eye disease diagnostic devices market in the U.S.
• Innovative technology and unique usability of dry eye diagnostic devices create a new standard for dry eye analysis
• These factors are anticipated to propel the dry eye disease diagnostic devices market in the U.S. during the forecast period

U.S. Dry Eye Disease Diagnostic Devices Market: Market Segmentation

• In terms of device type, the dry eye disease diagnostic devices market in the U.S. has been classified into anterior segment OCT (AS-OCT), meibography device, corneal topographer, osmolarity testing device, ocular surface thermographer, interferometer, fluorophotometer, and others
• Based on disease, the dry eye disease diagnostic devices market in the U.S. has been bifurcated into evaporative dry eye syndrome and aqueous dry eye syndrome
• In terms of end-user, the dry eye disease diagnostic devices market in the U.S. has been divided into hospitals, diagnostic centers, ophthalmology centers/clinic, and others
• Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The dry eye disease diagnostic devices market report provides current and expected revenue (US$ Mn) for each of these segments from 2023 to 2032, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2023 to 2032 along with market size estimations.

Meibography Devices Ensure Thorough Eye Examination with HD Definition Imaging Technology

Meibography is revolutionizing the U.S. dry eye disease diagnostic devices market. The high prevalence of meibomian gland dysfunction (MGD) among individuals is translating into value-grab opportunities for market stakeholders. As such, meibography is gaining popularity as a non-invasive screening tool for MGD and enables ophthalmologists to provide effective treatment to relieve dry eye symptoms.

Companies in the U.S. dry eye disease diagnostic devices market are increasing the availability of meibography devices to ensure a thorough clinical examination of the eyes with the help of high definition (HD) imaging technology. Eye doctors are using meibography devices to view the health of meibomian glands with optimum accuracy.

Prolonged Exposure to VDTs Increases Risk of DED amid Coronavirus Pandemic

The prolonged use of video display terminals (VDTs) has increased the risk of ocular surface disorders such as the dry eye disease (DED) amid the ongoing coronavirus pandemic. Stakeholders in the U.S. dry eye disease diagnostic devices market are gaining cognizance about these findings and increasing the availability of tools.

Even as DED is among the most common eye diseases in the U.S., the pandemic poses risks for DED patients. Nevertheless, participants in the U.S. dry eye disease diagnostic devices market are increasingly focusing on telehealth services and eHealth to stay future-ready in the healthcare landscape. Healthcare providers and med-tech companies are reinventing their care services and product distribution, respectively. The abusive use of mobile phones and TVs, owing to work-from-home settings may lead to poor quality of blinking, thus increasing the risk of DED.

Tests and Devices with Deep Learning Models Hold Potentials to Improve Patient Outcomes

Accurately diagnosing and managing DED is potentially challenging. It has been found that there is a lack of gold standard test for DED diagnosis. Hence, apart from increasing research in anterior segment optical coherence tomography (AS-OCT), med-tech companies are innovating in devices with high sensitivity, specificity, and accuracy for autonomously distinguishing DED from healthy patients.

Companies in the U.S. dry eye disease diagnostic devices market are developing deep learning models that use an end-to-end black box, which help to improve patient outcomes. The algorithm in this model helps to highlight the patterns of tear film-corneal epithelium during the occlusion, which indicates its efficacy for differentiating AS-OCT images.

Some of the prominent players in the Dry Eye Disease Diagnostic Devices Market include:

• Johnson & Johnson Services, Inc.
• OCULUS Optikgeräte GmbH
• Carl Zeiss Meditec AG
• TearLab Corporation
• Optovue, Inc.
• AXIM Biotechnologies
• Topcon Corporation
• Quantel Medical
• Essilor Instruments
• I-MED Pharma, Inc.
• Box Medical Solutions Inc.
• NIDEK CO., LTD.

Segments Covered in the Report

This report forecasts revenue growth and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Dry Eye Disease Diagnostic Devices market.

• Device Type
• Anterior Segment OCT (AS-OCT)
• Meibography Device
• Corneal Topographer
• Osmolarity Testing Device
• Ocular Surface Thermographer
• Interferometer
• Fluorophotometer
• Others
• Disease
• Evaporative Dry Eye Syndrome
• Aqueous Dry Eye Syndrome
• End-user
• Hospitals
• Diagnostic Centers
• Ophthalmology Centers/Clinic
• Others